Population pharmacokinetics of lamotrigine in Chinese children with epilepsy

Acta Pharmacologica Sinica

Volumn 33, Issue 11, 2012, Pages 1417-1423

  He, Da Ke ^a,b   Wang, Li ^a   Lu, Wei ^c   Qin, Jiong ^a   Zhang, Shen ^d   Li, Ling ^b   Zhang, Jian Ming ^b   Bao, Wei Qun ^b   Song, Xiao Qing ^b   Liu, Hai Tao ^b  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chinese children; epilepsy; Lamotrigine; NONMEM; population pharmacokinetics

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ANTICONVULSANT THERAPY; ARTICLE; CHILD; CHILDHOOD DISEASE; CHINESE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MONITORING; EPILEPSY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POPULATION MODEL; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; STEADY STATE;

ADOLESCENT; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; EPILEPSY; FEMALE; HUMANS; INFANT; MALE; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PRACTICE GUIDELINES AS TOPIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TRIAZINES;

EID: 84868531365     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.118     Document Type: Article

References (34)

1. Mullens EL. Clinical experience with lamotrigine monotherapy in adults with newly diagnosed epilepsy. Clin Drug Invest 1998; 16:125-33.
2. Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messen-heimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005; 65:1737-43.
3. Goa K, Ross SR, Chrisp P. Lamotrigine. A review of its pharmacological proper ties and clinical effcacy in epilepsy. Drugs 1993; 46:152-76.
4. Chong E, Dupuis LL. Therapeutic drug monitoring of lamotrigine. Ann Pharmacother 2002; 36:917-20.
5. Morris RG, Black AB, Harris AL, Batty AB, Sallustio BC. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 1998; 46:547-51.
6. Chen C. Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children. Br J Clin Pharmacol 2000; 50:135-45.
7. Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol 1999; 39:373-84.
8. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42:535-41.
9. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25:433-43.
10. Perucca E. The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia 1999; 40 (Suppl 9): S7-S13.
11. Jonsson EN, Karlsson MO. Xpose-An S-PLUS based population pharmacokinetic/pharma codynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58:51-64.
12. Vozeh S, Maitre PO, Stanski DR. Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J Pharmacokinet Biopharm 1990; 18:161-73.
13. Gidal BE, Anderson GD, Rutecki PR, Shaw R, Lanning A. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res 2000; 42:23-31.
14. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997; 43:457-65.
15. Chan V, Morris RG, Ilett KF, Tett SE. Population pharmacokinetics of lamotrigine. Ther Drug Monit 2001; 23:630-5.
16. Milovanovic JR, Jankovic SM. Population pharmacokinetics of lamotrigine in patients with epilepsy. Int J Clin Pharmacol Ther 2009; 47:752-60.
17. Garnett WR. Lamotrigine pharmacokinetics. J Child Neurol 1997; 12:10-5.
18. Armijo JA, Bravo J, Cuadrado A, Herranz JL. Lamotrigine serum con cen tration-to-dose ratio: influence of age and concomitant antiepileptic drug and dosage implications. Ther Drug Monit 1999; 21:182-90.
19. Fröscher W, Keller F, Vogt H, Krämer G. Prospective study on con-cen tration-effcacy and concentration-toxicity: correlations with lamo-trigine serum levels. Epileptic Disord 2002; 4:49-56.
20. Gidal BE, Welty TE. The concentration-effect relationship with lamotrigine (LTG). Epilepsia 1997; 38:260.
21. Kilpatrick ES, Forrest G, Brodie MJ. Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study. Epilepsia 1996; 37:534-8.
22. Biton V. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol 2006; 2:1009-18.
23. Almeida AM, Falcão AC, Sales F, Baldeiras I, Rocha MJ, Caramona MM. Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. Eur J Clin Pharmacol 2006; 62:737-42.
24. Posner J, Holdich T, Crome P. Comparison of lamotrigine pharma-cokinetics in young and elderly healthy volunteers. J Pharm Med 1991; 1:121-8.
25. Bialer M. The pharmacokinetics and interactions of new antiepileptic drugs: an overview. Ther Drug Monit 2005; 27:722-6.
26. Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Effect of anti-epileptic drug comedication on lamotrigine clearance. Arch Neurol 2005; 62:1432-6.
27. Rambeck B, Specht U, Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet. 1996; 31:309-24.
28. Bottiger Y, Svensson JO, Sthale L. Lamotrigine drug interactions in a TDM material. Ther Drug Monit 1999; 21:171-4.
29. Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 2000; 55:588-91.
30. Mataringa MI, May TW, Rambeck B. Does Lamotrigine influence valproate concentrations? Ther Drug Monit 2002; 24:631-6.
31. Anderson GD, Yau MK, Gidal BE, Harris SJ, Levy RH, Lai AA, et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996; 60:145-56.
32. Sheiner LB, Beal SL. NONMEM Users Guide, Parts I-VI. San Francisco: NONMEM Project Group, University of California San Francisco, 1989.
33. Castel-Branco MM, Almeida AM, Falcão AC, Macedo TA, Caramona MM, Lopez FG. Lamotrigine analysis in biological fluids by high performance liquid chromatography (HPLC). J Chromatography B Biomed Sci Appl 2001; 755:119-27.
34. Rivas N, Buelga DS, Elger CE, Santos-Borbujo J, Otero MJ, Domínguez-Gil A, et al. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. Ther Drug Monit 2008; 30:483-9.